Beyond amplifying inflammatory responses, activation of NLRP3 inflammasome also promotes liver fibrogenesis during NASH, as blockade of NLRP3 improves NASH pathology by simultaneously suppressing liver inflammation and fibrosis (78). This evidence concerns the gene NLRP3 and metabolic dysfunction-associated steatohepatitis.